Physician profile
David E Mangold
NPI 1164533618
$3,385.73
in general payments reported to CMS, 2019-2025
19 companies · $54.73 in 2025
The $54.73 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,522 · 2022: $107 · 2023: $671 · 2024: $1,030 · 2025: $54.73.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $881 · Food and Beverage: $876.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $881.00 |
| Food and Beverage | $875.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $1,171.99 | 2023-2024 | Ayvakit |
| Novartis Pharmaceuticals Corporation | $1,040.78 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $247.96 | 2021-2024 | Airsupra, Tezspire |
| Merck Sharp & Dohme LLC | $156.96 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $138.72 | 2021-2024 | Dupixent |
| Aimmune Therapeutics, INC. | $125.00 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $99.88 | 2021-2024 | Eohilia |
| Optinose US, INC. | $69.34 | 2021 | |
| Genzyme Corporation | $65.60 | 2023-2025 | |
| Astellas Pharma US INC | $48.81 | 2022 | |
| Genentech USA, INC. | $40.77 | 2021-2023 | Xolair |
| Ars Pharmaceuticals Operations, INC. | $40.21 | 2025 | Neffy |
| Glaxosmithkline, LLC. | $29.18 | 2021-2024 | Nucala |
| Pfizer INC. | $25.35 | 2022 | |
| Horizon Therapeutics Plc | $24.59 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $20.30 | 2024 | Actimmune |
| Incyte Corporation | $15.91 | 2023 | Opzelura |
| Leo Pharma INC. | $12.98 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $11.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Mangold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.